scholarly journals Application of In-Silico Reverse Vaccinology for Designing Multi-Epitope Vaccine Against Coronavirus

2020 ◽  
Author(s):  
Kumar Sharp ◽  
Dr. Shubhangi Dange
Keyword(s):  
Immune Response ◽  
In Silico ◽  
Reverse Vaccinology ◽  
Economic Losses ◽  
The Novel ◽  
Toll Like Receptor ◽  
Ramachandran Plot ◽  
Cell Mediated Immune Response ◽  
Specific Medication ◽  
Novel Coronavirus

In absence of any specific medication or vaccine till now, experimentation has reached new heights. With lockdown imposed in almost every country and huge economic losses the search for a suitable vaccine has still been unsuccessful. In this study we have approached through in-silico method or reverse vaccinology taking advantage of the genome sequence of the novel coronavirus. We created a multi-epitope model vaccine which can elicit both humoral as well as cell-mediated immune response. It is also docked with toll-like receptor 8 TLR-8. The sequence obtained is antigenic, non-allergenic and 86.3% residues are in favourable region of Ramachandran plot. This sequence might have good hope of emerging as the vaccine of the current pandemic if studied more in depth.

scholarly journals Application of In-Silico Reverse Vaccinology for Designing Multi-Epitope Vaccine Against Coronavirus

2020 ◽  
Author(s):  
Kumar Sharp ◽  
Dr. Shubhangi Dange
Keyword(s):  
Immune Response ◽  
In Silico ◽  
Reverse Vaccinology ◽  
Economic Losses ◽  
The Novel ◽  
Toll Like Receptor ◽  
Ramachandran Plot ◽  
Cell Mediated Immune Response ◽  
Specific Medication ◽  
Novel Coronavirus

In absence of any specific medication or vaccine till now, experimentation has reached new heights. With lockdown imposed in almost every country and huge economic losses the search for a suitable vaccine has still been unsuccessful. In this study we have approached through in-silico method or reverse vaccinology taking advantage of the genome sequence of the novel coronavirus. We created a multi-epitope model vaccine which can elicit both humoral as well as cell-mediated immune response. It is also docked with toll-like receptor 8 TLR-8. The sequence obtained is antigenic, non-allergenic and 86.3% residues are in favourable region of Ramachandran plot. This sequence might have good hope of emerging as the vaccine of the current pandemic if studied more in depth.

The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking

2020 ◽  
Vol 23 ◽  
Author(s):  
Sisir Nandi ◽  
Mohit Kumar ◽  
Mridula Saxena ◽  
Anil Kumar Saxena
Keyword(s):  
Molecular Docking ◽  
In Silico ◽  
Drug Repurposing ◽  
Clinical Settings ◽  
The Novel ◽  
In Silico Docking ◽  
Biochemical Mechanisms ◽  
Novel Coronavirus ◽  
In Silico Molecular Docking

Background: The novel coronavirus disease (COVID-19) is caused by a new strain (SARS-CoV-2) erupted in 2019. Nowadays, it is a great threat that claims uncountable lives worldwide. There is no specific chemotherapeutics developed yet to combat COVID-19. Therefore, scientists have been devoted in the quest of the medicine that can cure COVID- 19. Objective: Existing antivirals such as ASC09/ritonavir, lopinavir/ritonavir with or without umifenovir in combination with antimalarial chloroquine or hydroxychloroquine have been repurposed to fight the current coronavirus epidemic. But exact biochemical mechanisms of these drugs towards COVID-19 have not been discovered to date. Method: In-silico molecular docking can predict the mode of binding to sort out the existing chemotherapeutics having a potential affinity towards inhibition of the COVID-19 target. An attempt has been made in the present work to carry out docking analyses of 34 drugs including antivirals and antimalarials to explain explicitly the mode of interactions of these ligands towards the COVID-19protease target. Results: 13 compounds having good binding affinity have been predicted towards protease binding inhibition of COVID-19. Conclusion: Our in silico docking results have been confirmed by current reports from clinical settings through the citation of suitable experimental in vitro data available in the published literature.

In Silico Approaches for Novel Drug Discovery Against Coronavirus by Employing the Hybrid Molecular Technique: A Review

2021 ◽  
pp. 1-8
Author(s):  
Noor ul Amin Mohsin ◽  
Muhammad Irfan ◽  
Muhammad Naeem Aamir
Keyword(s):  
In Silico ◽  
Antiviral Agent ◽  
Molecular Technique ◽  
The Novel ◽  
Hybrid Molecules ◽  
The World ◽  
Being There ◽  
Novel Coronavirus ◽  
Novel Drug ◽  
Day By Day

The coronavirus disease (COVID-19) is causing havoc all around the world. The number of active cases and deaths is increasing day by day. The novel coronavirus (CoV) is the causative agent of this disease. For the time being, there is no specific antiviral agent for the cure of COVID-19. A variety of drugs are being repurposed to counteract this disease. Scientists all over the world are striving to get some ideal molecules against this pandemic. Some hybrid molecules have been designed by coupling the privileged scaffolds of known antiviral and antimalarial drugs. This review deals with the hybrid molecules that have been designed and evaluated against the known targets of CoV by in silico techniques.

scholarly journals Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes

Endocrinology ◽  
2020 ◽  
Vol 161 (9) ◽  
Author(s):  
Franck Mauvais-Jarvis ◽  
Sabra L Klein ◽  
Ellis R Levin
Keyword(s):  
Immune Response ◽  
Distress Syndrome ◽  
Immune Dysregulation ◽  
Innate Immune ◽  
The Novel ◽  
Cytokine Storm ◽  
Inflammatory Infiltration ◽  
Biological Sex ◽  
17Β Estradiol ◽  
Novel Coronavirus

Abstract Severe outcomes and death from the novel coronavirus disease 2019 (COVID-19) appear to be characterized by an exaggerated immune response with hypercytokinemia leading to inflammatory infiltration of the lungs and acute respiratory distress syndrome. Risk of severe COVID-19 outcomes is consistently lower in women than men worldwide, suggesting that female biological sex is instrumental in protection. This mini-review discusses the immunomodulatory and anti-inflammatory actions of high physiological concentrations of the steroids 17β-estradiol (E2) and progesterone (P4). We review how E2 and P4 favor a state of decreased innate immune inflammatory response while enhancing immune tolerance and antibody production. We discuss how the combination of E2 and P4 may improve the immune dysregulation that leads to the COVID-19 cytokine storm. It is intended to stimulate novel consideration of the biological forces that are protective in women compared to men, and to therapeutically harness these factors to mitigate COVID-19 morbidity and mortality.

scholarly journals Psychological Effects of the Coronavirus Disease 2019 Pandemic

2020 ◽  
Vol 95 (6) ◽  
pp. 360-363
Author(s):  
Minyoung Sim
Keyword(s):  
Psychological Distress ◽  
Social Interactions ◽  
Preventive Measures ◽  
Psychological Effects ◽  
Economic Losses ◽  
The Novel ◽  
Loss Of Autonomy ◽  
The World ◽  
Secondary Stressors ◽  
Novel Coronavirus

The novel coronavirus disease 2019 (COVID-19) pandemic has spread across the world, reducing social interactions and causing substantial psychological distress and economic losses. This review summarizes the psychological effects of the COVID-19 pandemic in terms of uncertainty, the loss of autonomy associated with preventive measures, and secondary stressors such as potential future economic losses.

scholarly journals In silico characterization of the NiRAN domain of RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV2

2020 ◽  
Author(s):  
Abhisek Dwivedy ◽  
Richard Mariadasse ◽  
Mohammed Ahmed ◽  
Deepsikha Kar ◽  
Jeyaraman Jeyakanthan ◽  
...  
Keyword(s):  
Active Site ◽  
In Silico ◽  
3D Structure ◽  
Drug Repurposing ◽  
The Novel ◽  
Lead Compounds ◽  
Nucleotidyl Transferase ◽  
Domain Organisation ◽  
Novel Coronavirus ◽  
In Silico Characterization

Apart from the canonical fingers, palm and thumb domains, the RNA dependent RNA polymerases (RdRp) from the viral order Nidovirales possess two additional domains. Of these, the function of the Nidovirus RdRp associated nucleotidyl transferase domain (NiRAN) remains unanswered. The elucidation of the 3D structure of the RdRp from the novel coronavirus – SARS-CoV2, provided the first ever insights into the domain organisation and possible functional characteristics of the NiRAN domain. Using in silico tools, this study predicts that the NiRAN domain assumes a kinase or phosphotransferase like fold and binds GTP and UTP at its proposed active site. Additionally, using molecular docking this study predicts the binding of five well characterized anti-microbial compounds at the NiRAN domain active site and their drug-likeliness and DFT properties. In line with the current global COVID-19 pandemic urgency, this study provides a new target and potential lead compounds for drug repurposing against SARS-CoV2.

Insights into pathophysiology, immune response and treatment of novel CoVID-19

2021 ◽  
Vol 16 (10) ◽  
pp. 189-197
Author(s):  
Manpreet Kaur ◽  
Rajinder Kaur ◽  
Reena Gupta
Keyword(s):  
Immune Response ◽  
World Health ◽  
The Novel ◽  
Asian Countries ◽  
Human Lungs ◽  
Potential Vaccine ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Droplets ◽  
Alveolar Edema

The beginning of year 2020 has brought with it mass destruction of mankind in form of novel coronavirus, named as CoVID-19. Declared as pandemic by World Health Organization (WHO), CoVID-19 has its origin in bats and pangolin from which it was probably transferred to human. Subsequent human to human transmission has been seen by respiratory droplets, fomites and oral-fecal route. The disease has caused widespread deaths in America, China, France and Italy followed by many European and Asian countries. CoVID-19 targets the human lungs and multiplies in alveoli using host machinery. Interstitial edema and alveolar edema at later stages cause alveoli collapse and difficulty in breathing. Severe cases may pave to systemic inflammatory response that has fatal response in body. Unfortunately, researchers are still struggling for potential vaccine or promising drug to combat the disease. WHO has issued guidelines suggesting regular hand washing, social distancing, wearing masks and quarantination as the best ways to prevent infection. This review gives an overview of the novel CoVID-19, conditions and immune response of human body related with it.

scholarly journals Inflammatory pathways and potential therapies for COVID-19: A mini review

2021 ◽  
Vol 19 ◽  
pp. 205873922110029
Author(s):  
Areeg M Dabbish ◽  
Nouran Yonis ◽  
Mohamed Salama ◽  
Musthafa M Essa ◽  
M Walid Qoronfleh
Keyword(s):  
Immune Response ◽  
Proinflammatory Cytokines ◽  
Interferon Response ◽  
The Novel ◽  
Health Crisis ◽  
The Public ◽  
Repurposed Drugs ◽  
Novel Virus ◽  
Novel Coronavirus

The public health crisis of the novel coronavirus disease (COVID-19) is alarming since January 2020. COVID-19 genome (SARS-CoV-2) is related to other highly pathogenic coronaviruses SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus). Amino acid substitutions in some of SARS-CoV-2 proteins resulted in mutations proposing more virulent and contagious properties for this novel virus. Coronavirus penetrates the host cell via endocytosis and once infected, immune responses are triggered to fight against the pathogen. Innate immune response activates major transcription factors to secrete proinflammatory cytokines and type 1 interferon response (T1INF) to induce antiviral immunity. While adaptive immunity initiates cascade of B-cells antibody mediated and T-cells cellular mediate immunities, several mechanisms are raised by SARS-CoV-2 to evade host immune response. Consequently, a surge of proinflammatory cytokines, known as cytokine storm (CS) are released. Failure to manage CS results in several pathological complications as acute respiratory distress syndrome (ARDS). Although researches have not discovered an effective treatment against SARS-CoV-2, recent therapeutic approaches recommending the use of anti-inflammatories in combination with antivirals and some repurposed drugs for COVID-19 patients. Future medications should be designed to target essential hallmarks in the CS to improve clinical outcomes.

scholarly journals SARS-CoV-2 infection and the antiviral innate immune response

2020 ◽  
Author(s):  
Hui Yang ◽  
Yingying Lyu ◽  
Fajian Hou
Keyword(s):  
Immune Response ◽  
Innate Immune Response ◽  
Clinical Manifestations ◽  
Innate Immune ◽  
World Health ◽  
The Novel ◽  
Global Public Health ◽  
Replication Process ◽  
Novel Coronavirus ◽  
Health Organization

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began in December 2019, causing the illness known as the novel coronavirus disease 2019 (COVID-19). The virus spread rapidly worldwide to become a global public health emergency. As of 15 November 2020, more than 53 million confirmed cases and over one million deaths worldwide have been reported (World Health Organization, 2020). The SARS-CoV-2 genome was sequenced and studies are ongoing to further understand the epidemiology, clinical manifestations, etiological structure, cellular receptor angiotensin II converting enzyme (ACE2), and intracellular replication process of the virus. Currently, thousands of clinical trials related to SARS-CoV-2 are underway (https://clinicaltrials.gov/). However, no vaccines or drugs have yet been approved, until very recently, for direct treatment or prevention of COVID-19 and only supportive treatment has been applied clinically. This review will discuss the possible mechanism of the innate immune response to SARS-CoV-2 infection and provide insight into the development of related therapeutics.

scholarly journals Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0247797
Author(s):  
Renee L. Higgins ◽  
Stephen A. Rawlings ◽  
Jamie Case ◽  
Florence Y. Lee ◽  
Clarence W. Chan ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Vaccine Development ◽  
Treatment Strategies ◽  
Lateral Flow ◽  
Patient Specific ◽  
The Novel ◽  
Successful Vaccine ◽  
Novel Coronavirus ◽  
Antibody Levels

Since the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body’s temporal immune response against SARS-CoV-2 is paramount to successful vaccine development and disease progression monitoring. To provide insight into the antibody response against SARS-CoV-2, plasma samples from 181 PCR-confirmed COVID-19 patients collected at various timepoints post-symptom onset (PSO) were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies via lateral flow. Additionally, 21 donors were tracked over time to elucidate patient-specific immune responses. We found sustained levels of anti-SARS-CoV-2 antibodies past 130 days PSO, with 99% positivity observed at 31–60 days PSO. By 61–90 days PSO, the percentage of IgM-/IgG+ results were nearly equal to that of IgM+/IgG+ results, demonstrating a shift in the immune response with a decrease in IgM antibody levels. Results from this study not only provide evidence that the antibody response to COVID-19 can persist for over 4 months, but also demonstrates the ability of Easy Check™ to monitor seroconversion and antibody response of patients. Easy Check was sufficiently sensitive to detect antibodies in patient samples as early as 1–4 days PSO with 86% positivity observed at 5–7 days PSO. Further studies are required to determine the longevity and efficacy of anti-SARS-CoV-2 antibodies, and whether they are protective against re-infection.

Sign in / Sign up

Export Citation Format

Share Document